Drug Profile
Research programme: malaria therapeutics - Carna Biosciences
Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Carna Biosciences; Kitasato University
- Class Antimalarials; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for research development in Malaria in Japan
- 28 Aug 2020 No recent reports of development identified for research development in Malaria in USA
- 01 Aug 2019 Malaria therapeutics - Carna Biosciences is available for licensing as of 01 Aug 2019. https://www.carnabio.com/